Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Gains from Investment Securities (2024 - 2025)

Xilio Therapeutics' Gains from Investment Securities history spans 2 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 86.15% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $3.9 million, up 86.15%, while the annual FY2024 figure was $8.3 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q3 2025 was $3.9 million at Xilio Therapeutics, up from $574911.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.9 million in Q1 2025 and bottomed at $574911.0 in Q2 2025.